ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BỆNH BẠCH CẦU MẠN DÒNG TUỶ BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ

Abstract

Background: Imatinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia (CML) in Vietnam. However, there is currently a lack of research data on treatment outcomes with this drug in Can Tho. Objectives: To evaluate the clinical characteristics, laboratory findings, and treatment outcomes of patients with CML treated with Imatinib at Can Tho Hematology and Blood Transfusion Hospital. Materials and methods: A non-controlled interventional study was conducted on 34 CML patients diagnosed and treated at Can Tho Hematology and Blood Transfusion Hospital. Results: The male-to-female ratio was approximately 1.27, with a mean age of 51.74 ± 16.31 years, the majority being 40 years or older. Splenomegaly was the most common clinical manifestation, observed in 70.6% of patients, followed by hepatomegaly (55.9%), fatigue (50%), and fever (50%). Prior to treatment, the median leukocyte count was 79.61 (Q1-Q3: 20.95-164.83) G/L, while the mean hemoglobin and platelet levels were 10.46 ± 2.44 g/dL and 504.15 ± 280.34 G/L, respectively. After three months of imatinib therapy, hemoglobin levels increased to 11.54 ± 1.94 g/dL, while leukocyte and platelet counts decreased to 6.74 (4.82-8.21) G/L and 196.26 ± 96.17 G/L, respectively. These changes were statistically significant (p < 0.05). The overall response rate was 82.4%. Conclusion: After three months of imatinib therapy, the majority of CML patients demonstrated significant improvements in peripheral blood parameters.